XML 108 R91.htm IDEA: XBRL DOCUMENT v3.25.0.1
Note T - Merger (Details Textual)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Nov. 22, 2023
shares
Nov. 17, 2023
USD ($)
$ / shares
shares
Aug. 30, 2023
USD ($)
shares
Jun. 16, 2023
USD ($)
$ / shares
shares
Jan. 31, 2023
USD ($)
shares
Mar. 14, 2022
USD ($)
Nov. 30, 2023
shares
Dec. 31, 2024
USD ($)
shares
Dec. 31, 2023
USD ($)
shares
Oct. 31, 2023
USD ($)
Stock Issued During Period, Shares, Acquisitions (in shares) | shares             1,382,489   7,530,509  
Stock Issued During Period, Shares, New Issues (in shares) | shares               10,615,385    
Stock Issued During Period, Value, New Issues                 $ 6,106  
The Investor Warrant [Member]                    
Stock Issued During Period, Shares, New Issues (in shares) | shares 917,934           917,934      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares 2,920,306           2,920,306      
SWK Loans [Member]                    
Payments to Acquire Notes Receivable     $ 12,000   $ 12,000          
Stock Issued During Period, Shares, Acquisitions (in shares) | shares     98,683   98,683          
Marathon Convertible Notes [Member]                    
Stock Issued During Period, Shares, Acquisitions (in shares) | shares       2,171,038            
Asset Acquisition, Share Price (in dollars per share) | $ / shares       $ 5.0667            
Asset Acquisition, Consideration Transferred       $ 11,000            
SWK Loans and Marathon Notes [Member]                    
Payments to Acquire Notes Receivable   $ 12,000                
Stock Issued During Period, Shares, Acquisitions (in shares) | shares   2,270,000                
Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable   $ 11,500                
VWAP, Consecutive Trading Days (Year)   20 years                
Nantahala Note [Member]                    
Debt Instrument, Face Amount   $ 5,000 $ 5,000   $ 5,000          
Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member]                    
Maximum Royalty Percentage     20.00%              
Upfront Payment     $ 10,000              
Addiitonal Payment on First Anniversary     1,500              
Maximum Royalty Obligation     $ 45,000              
Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member] | Europe [Member]                    
Maximum Royalty Percentage     10.00%              
Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member] | Worldwide, Excluding Europe [Member]                    
Maximum Royalty Percentage     10.00%              
Acer Therapeutics Inc [Member] | SWK Loans [Member]                    
Proceeds from Issuance of Long-Term Debt         $ 7,000 $ 6,500        
Maximum [Member] | Acer Therapeutics Inc [Member] | License Agreement and Termination Agreement [Member] | Relief [Member]                    
Contractual Obligation     $ 56,500              
Bridge Loan [Member]                    
Financing Receivable, Maximum Limit     18,000             $ 18,000
Bridge Loan [Member] | Minimum [Member]                    
Financing Receivable, Maximum Limit     16,500              
Acer Therapeutics Inc [Member]                    
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Conversion Ratio   0.121                
Business Acquisition, Share Price (in dollars per share) | $ / shares   $ 0.0001                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   $ 76,000                
Business Combination, Consideration Transferred   $ 72,600                
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares   2,960,000                
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable   $ 12,800                
Business Combination, Contingent Consideration, Liability   8,500           $ 3,500 $ 7,262  
Repayments of Notes Payable   $ 1,000                
Gain (Loss) on Contingent Consideration, Change in Fair Value               $ 3,700    
Acer Therapeutics Inc [Member] | Acer Warrants [Member]                    
Stock Issued During Period, Shares, New Issues (in shares) | shares   900,000                
Stock Issued During Period, Value, New Issues   $ 4,000                
Acer Therapeutics Inc [Member] | Bridge Loan [Member]                    
Business Combination, Consideration Transferred, Other   $ 17,800 $ 16,500